IgA Nephropathy Pipeline Analysis 2025

IgA nephropathy, or Berger's disease is a condition brought on by immunoglobulin A (IgA) buildup in the kidneys' filtering units, or glomeruli. Over time, inflammation brought on by this accumulation may impede renal function. Although the precise etiology is uncertain, infections or genetic factors may be involved. Swelling, proteinuria, and blood in the urine are common symptoms. It can develop into renal failure if treatment is not received. Symptom management, blood pressure control, and perhaps immunosuppressive medicine are all part of the treatment. The rising number of cases is anticipated to impact the pipeline landscape for IgA nephropathy emerging drugs positively.

Report Coverage

The IgA Nephropathy Drug Pipeline Insight Report by the publisher gives comprehensive insights into IgA nephropathy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for IgA nephropathy. The IgA nephropathy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The IgA nephropathy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with IgA nephropathy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to IgA Nephropathy.

IgA Nephropathy Pipeline Outlook

When immunoglobulin A (IgA) is inappropriately deposited in the glomeruli, it triggers an inflammatory response that results in IgA nephropathy. IgA and other proteins produce immune complexes that activate complement and attract inflammatory cells, causing damage to kidney tissue. Reduced filtration, glomerular damage, and the development of chronic kidney disease are the outcomes of this. Repeated inflammation over time can cause kidney failure, fibrosis, and scarring.

IgA Nephropathy therapeutics include telitacicept, atrasentan, among others. The use of monoclonal antibodies to treat IgA nephropathy is being investigated. To lessen inflammation and stop additional kidney injury, these antibodies target particular immunological pathways, such as those involving B cells or the complement system. Monoclonal antibody treatments, such as those that target complement or CD20, are being researched to help individuals with IgA nephropathy. Further, the rising focus on the development of IgA Nephropathy emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.

IgA Nephropathy Epidemiology

IgA nephropathy is thought to affect 2.5 out of every 100,000 people worldwide, with higher rates seen in East Asia, where it may be the cause of up to 40% of kidney biopsies. Due to variations in diagnosis procedures and population composition, the prevalence is lower in North America (10%) and Europe (20-30%). The male-to-female ratio ranges from 2:1 to 6:1, with males being the condition's primary victims.

IgA Nephropathy - Drug Pipeline Therapeutic Assessment

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for IgA nephropathy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of IgA nephropathy drug candidates.

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibody
• Peptide
• Others

By Route of Administration

• Oral
• Parenteral
• Others

IgA Nephropathy - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II and III cover a major share of the total clinical trials, with a substantial number of IgA Nephropathy drugs undergoing clinical development.

IgA Nephropathy - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under IgA nephropathy pipeline analysis include small molecules, monoclonal antibodies and peptides among others. The IgA nephropathy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for IgA nephropathy.

IgA Nephropathy Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the IgA nephropathy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed IgA nephropathy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in IgA nephropathy clinical trials:

• RemeGen Co., Ltd.
• Chinook Therapeutics, Inc.
• Travere Therapeutics, Inc.
• Arrowhead Pharmaceuticals
• Chengdu Suncadia Medicine Co., Ltd.
• Biocity Biopharmaceutics Co., Ltd.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Takeda Pharmaceuticals
• Alexion Pharmaceuticals, Inc.
• Novartis Pharmaceuticals

IgA Nephropathy Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Telitacicept

Sponsored by RemeGen Co., Ltd., the objective of this multicenter clinical trial is to investigate the efficacy and safety of the IgA nephropathy drug candidate, Telitacicept in the affected patients. The study is under Phase III clinical development and has an estimated 90 participants.

Drug: Atrasentan

Chinook Therapeutics is conducting a Phase III study aimed at examining the efficacy of the investigational drug atrasentan for the treatment of IgA nephropathy. The interventional study has enrolled about 320 subjects with patients with biopsy-proven IgAN.

Reasons To Buy This Report

The IgA Nephropathy Drug Report provides a strategic overview of the latest and future landscape of treatments for IgA Nephropathy. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within IgA nephropathy pipeline insights.

Key Questions Answered in the IgA Nephropathy - Pipeline Insight Report

• What is the current landscape of IgA nephropathy disease pipeline drugs?
• Which companies/institutions are developing IgA nephropathy disease emerging drugs?
• How many phase II drugs are currently present in IgA nephropathy disease pipeline drugs?
• Which company is leading the IgA nephropathy disease pipeline development activities?
• What is the current IgA nephropathy disease therapeutic assessment?
• What are the opportunities and challenges present in the IgA nephropathy disease drug pipeline landscape?
• What is the efficacy and safety profile of IgA nephropathy disease pipeline drugs?
• Which companies/institutions are involved in IgA nephropathy disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in IgA nephropathy disease?

This product will be delivered within 3-5 business days.